首页> 外文期刊>Cardiovascular Diabetology >Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides
【24h】

Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides

机译:糖尿病患者左心室舒张功能障碍的早期诊断:利钠肽的可能作用

获取原文
           

摘要

Background The aim of the present study was to verify whether BNP might detect pre-clinical diastolic dysfunction (LVDD) in type-2 diabetic patients. Methods One-hundred and twenty-seven consecutive outpatients with type-2 diabetes mellitus were enrolled into the study. Subjects with overt heart failure or NYHA class > 1, history of coronary artery disease, severe valvulopathy or chronic atrial fibrillation were excluded from the study. All patients underwent clinical evaluation, laboratory assessment of brain natriuretic peptide (BNP) and echocardiographic examination. Results No patients showed systolic impairment of left ventricular function, whereas diastolic dysfunction was detected in 53 (42%) cases (all impaired relaxation). Median BNP was 27 pg/ml without any significant difference between 76 patients with normal left ventricular function and 53 with diastolic dysfunction; in 54 (43%) patients showing HBA1C≥8 (uncontrolled diabetes) normal function was found in 32 and diastolic dysfunction in 22, with a significant difference of BNP at multivariate analysis (OR = 1.02, 95%CI = 1.05-1.09, p = 0.003). In uncontrolled diabetic cohort, BNP was a strong predictor for LVDD (OR = 2.7, 95%CI = 1.3-5.6, p = 0.006) along with the duration of diabetes (OR = 1.6, 95%CI = 1.1-2.9, p = 0.046). BNP > 25 pg/ml was a cut-off value with high accuracy to detect a LVDD. Discussion Early screening of high-risk patients for diabetic cardiomyopathy development might be useful to better control glycemic profile in order to reduce heart disease progression or even to reverse it Conclusions BNP could be a cheap, easy and useful tool to screen those ones with preclinical ventricular diastolic dysfunction in a subset of patients particularly prone to develop cardiovascular complications, like uncontrolled diabetic patients.
机译:背景技术本研究的目的是验证BNP是否可以检测2型糖尿病患者的临床前舒张功能障碍(LVDD)。方法招募一百二十七名连续的2型糖尿病门诊患者。明显心力衰竭或NYHA> 1级的受试者被排除在冠状动脉疾病,严重的瓣膜病或慢性心房颤动的病史之外。所有患者均接受临床评估,脑钠肽(BNP)的实验室评估和超声心动图检查。结果没有患者显示左心室收缩功能受损,而53例(42%)病例发现舒张功能障碍(所有舒张功能受损)。 BNP中位数为27 pg / ml,在76例左室功能正常的患者和53例舒张功能障碍的患者之间没有显着差异。 54例(43%)HBA1C≥8(糖尿病未控制)的患者中32例功能正常,舒张功能障碍22例,在多变量分析中BNP差异显着(OR = 1.02,95%CI = 1.05-1.09,p = 0.003)。在无控制的糖尿病队列中,BNP是糖尿病持续时间(OR = 1.6,95%CI = 1.1-2.9,p = 2)的强预测指标(VDD = 2.7,95%CI = 1.3-5.6,p = 0.006)。 0.046)。 BNP> 25 pg / ml是检测LVDD的高精度截止值。讨论早期筛查糖尿病性心肌病高危患者可能有助于更好地控制血糖水平,以减少心脏病的进展甚至逆转结论。结论BNP可能是一种廉价,简便且有用的工具,可用于筛查那些患有临床前心室的人像不受控制的糖尿病患者一样,在一部分患者中特别容易发生心血管并发症的心脏舒张功能障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号